Дислипидемия и стратегии медикаментозной гиполипидемической терапии у пациентов, получающих заместительную почечную терапию: обзор литературы

Дислипидемия у пациентов с хронической болезнью почек (ХБП), особенно получающих заместительную почечную терапию (ЗПТ), является одним из важных факторов риска сердечно-сосудистых осложнений. Патогенез нарушений липидного обмена имеет множество факторов, связанных с ХБП и особенностями ЗПТ и иммуносупрессии. Стратегии терапии, направленные на коррекцию дислипидемии у таких пациентов, мало изучены. В работе проанализированы методы медикаментозного лечения дислипидемии и возможности их применения у данной группы пациентов. Поиск литературы производился по электронным базам данных Medline/PubMed (https://pubmed.ncbi.nlm.nih.gov)  и eLIBRARY/Российский индекс научного цитирования  (https://www.elibrary.ru).

1. Del Vecchio L., Baragetti I., Locatelli F. New agents to reduce cholesterol levels: implications for nephrologists //Nephrology Dialysis Transplantation. – 2020. – Т. 35. – №. 2. – С. 213-218. doi: 10.1093/ndt/gfz013. PMID: 30753594.

2. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-1635. doi: 10.1161/CIR.0000000000001184. PMID: 37807924.

3. Шутов Е.В., Николаев А.Ю., Филатова Н.Н. Кардиоренальный синдром у больных на заместительной почечной терапии (Обзор литературы). Нефрология и диализ. 2018;20(3):262-273. doi: 10.28996/2618-9801-2018-3-262-273.

4. Lacount S, Tannock LR, Feingold KR, Ahmed SF, Anawalt B, Blackman MR et al. Dyslipidemia in Chronic Kidney Disease. 2025. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 26247091.

5. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 1997;277(7):582-94. PMID: 9032168.

6. Dawber TR, Kannel WB, Revotskie N, Kagan A. The epidemiology of coronary heart disease--the Framingham enquiry. Proc R Soc Med. 1962; 55(4):265-71. doi: 10.1177/003591576205500403. PMID: 13884013

7. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med. 1979; 90(1):85-91. doi: 10.7326/0003-4819-90-1-85. PMID: 217290.

8. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1):111-188. doi: 10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020 Nov 21;41(44):4255. doi: 10.1093/eurheartj/ehz826. PMID: 31504418.

9. Noels H, Lehrke M, Vanholder R, Jankowski J. Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nat Rev Nephrol. 2021; 17(8):528-542. doi: 10.1038/s41581-021-00423-5. PMID: 33972752

10. Harlacher E, Wollenhaupt J, Baaten CCFMJ, Noels H. Impact of Uremic Toxins on Endothelial Dysfunction in Chronic Kidney Disease: A Systematic Review. Int J Mol Sci. 2022 Jan 4;23(1):531. doi: 10.3390/ijms23010531. PMID: 35008960

11. Rysz J, Franczyk B, Ławiński J, Gluba-Brzózka A. Oxidative Stress in ESRD Patients on Dialysis and the Risk of Cardiovascular Diseases. Antioxidants (Basel). 2020; 9(11):1079. doi: 10.3390/antiox9111079. PMID: 33153174

12. Suh SH, Kim SW. Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview. Diabetes Metab J. 2023; 47(5):612-629. doi: 10.4093/dmj.2023.0067. Epub 2023. PMID: 37482655

13. Cao H, Meng X. HDL and Kidney Diseases. Adv Exp Med Biol. 2022; 1377:163-170. doi: 10.1007/978-981-19-1592-5_13. PMID: 35575929.

14. Gusev E, Sarapultsev A. Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes. Int J Mol Sci. 2023; 24(9):7910. doi: 10.3390/ijms24097910. PMID: 37175617

15. Marsche G, Heine GH, Stadler JT, Holzer M. Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease. Biomolecules. 2020; 10(9):1348. doi: 10.3390/biom10091348. PMID: 32967334

16. Speer T, Ridker PM, von Eckardstein A, Schunk SJ, Fliser D. Lipoproteins in chronic kidney disease: from bench to bedside. Eur Heart J. 2021; 42(22):2170-2185. doi: 10.1093/eurheartj/ehaa1050. PMID: 33393990

17. Carty JR, Anastasopoulou C. Lecithin-Cholesterol Acyltransferase Deficiency. 2024. In: StatPearls [Internet]. Treasure Island (FL): StatPearls. PMID: 38753926

18. Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2019; 15(2):121. doi: 10.1038/s41581-018-0099-y. PMID: 30361677

19. Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, et al. Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules. 2023; 28(3):969. doi: 10.3390/molecules28030969. PMID: 36770634

20. Ma Z, Zhong J, Tu W, Li S, Chen J. The functions of apolipoproteins and lipoproteins in health and disease. Mol Biomed. 2024; 5(1):53. doi: 10.1186/s43556-024-00218-7. PMID: 39465476

21. Ren X, Zhang Z, Yan Z. Association Between Lipoprotein (A) and Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis. Front Endocrinol (Lausanne). 2021; 12:633529. doi: 10.3389/fendo.2021.633529. PMID: 33841331

22. Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022; 349:53-62. doi: 10.1016/j.atherosclerosis.2022.04.006. PMID: 35606076

23. Guarnieri G, Zanetti M, Vinci P, Cattin MR, Barazzoni R. Insulin resistance in chronic uremia. J Ren Nutr. 2009; 19(1):20-4. doi: 10.1053/j.jrn.2008.11.014. PMID: 19121765

24. Freeman AM, Acevedo LA, Pennings N. Insulin Resistance. 2023 Aug 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 29939616

25. Stegmayr B, Zuo L, Zadora W. Lipid and Bone Effects of Heparin Use During Hemodialysis. Semin Nephrol. 2023;43(6):151480. doi: 10.1016/j.semnephrol.2023.151480. PMID: 38195305

26. Zhu S, Zhang F, Shen AW, Sun B, Xia TY, Chen WS, et al. Metabolomics Evaluation of Patients With Stage 5 Chronic Kidney Disease Before Dialysis, Maintenance Hemodialysis, and Peritoneal Dialysis. Front Physiol. 2021; 11:630646. doi: 10.3389/fphys.2020.630646. PMID: 33551851

27. Liakopoulos V, Roumeliotis S, Zarogiannis S, Eleftheriadis T, Mertens PR. Oxidative stress in hemodialysis: Causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial. 2019; 32(1):58-71. doi: 10.1111/sdi.12745. PMID: 30288786

28. Cheng XBJ, Bargman J. Complications of Peritoneal Dialysis Part II: Nonmechanical Complications. Clin J Am Soc Nephrol. 2024; 19(6):791-799. doi: 10.2215/CJN.0000000000000418. PMID: 38190143

29. Aggarwal HK, Jain D, Lathar M, Yadav RK, Sawhney A. Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease. Ren Fail. 2010; 32(6):647-52. doi: 10.3109/0886022X.2010.486097. PMID: 20540630

30. Chmielnicka K, Heleniak Z, Debska-Slizien A. Dyslipidemia in Renal Transplant Recipients. Transplantology. 2022;3:188-199. doi: 10.3390/transplantology3020020

31. Rahimi L, Rajpal A, Ismail-Beigi F. Glucocorticoid-Induced Fatty Liver Disease. Diabetes Metab Syndr Obes. 2020; 13:1133-1145. doi: 10.2147/DMSO.S247379. PMID: 32368109

32. Rostaing L, Jouve T, Terrec F, Malvezzi P, Noble J. Adverse Drug Events after Kidney Transplantation. J Pers Med. 2023; 13(12):1706. doi: 10.3390/jpm13121706. PMID: 38138933

33. Iannuzzo G, Cuomo G, Di Lorenzo A, Tripaldella M, Mallardo V, Iaccarino Idelson P, et al. Dyslipidemia in Transplant Patients: Which Therapy? J Clin Med. 2022; 11(14):4080. doi: 10.3390/jcm11144080. PMID: 35887846

34. Al-Kuraishy HM, Sulaiman GM, Mohsin MH, Mohammed HA, Dawood RA, Albuhadily AK, et al. Targeting of AMPK/MTOR signaling in the management of atherosclerosis: Outmost leveraging. Int J Biol Macromol. 2025; 309(Pt 2):142933. doi: 10.1016/j.ijbiomac.2025.142933. PMID: 40203916

35. Arvanitis M, Lowenstein CJ. Dyslipidemia. Ann Intern Med. 2023; 176(6):ITC81-ITC96. doi: 10.7326/AITC202306200. PMID: 37307585

36. Wanner C, Tonelli M; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014; 85(6):1303-9. doi: 10.1038/ki.2014.31. PMID: 24552851

37. Ponticelli C, Arnaboldi L, Moroni G, Corsini A. Treatment of dyslipidemia in kidney transplantation. Expert Opin Drug Saf. 2020; 19(3):257-267. doi: 10.1080/14740338.2020.1732921. PMID: 32073914

38. Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al.; RACING investigators. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022; 400(10349):380-390. doi: 10.1016/S0140-6736(22)00916-3. PMID: 35863366

39. Michaeli DT, Michaeli JC, Albers S, Boch T, Michaeli T. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. Am J Cardiovasc Drugs. 2023; 23(5):477-495. doi: 10.1007/s40256-023-00594-5. PMID: 37486464

40. Luo B, Zhong S, Wang X, Guo P, Hou Y, Di W. Management of blood lipids in post-kidney transplant patients: a systematic review and network meta-analysis. Front Pharmacol. 2024; 15:1440875. doi: 10.3389/fphar.2024.1440875. PMID: 39439889

41. Canfora I, Pierno S. Hypertriglyceridemia Therapy: Past, Present and Future Perspectives. Int J Mol Sci. 2024;25(17):9727. doi: 10.3390/ijms25179727. PMID: 39273674

42. Pontremoli R, Bellizzi V, Bianchi S, Bigazzi R, Cernaro V, Del Vecchio L, et al. Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol. 2020; 33(3):417-430. doi: 10.1007/s40620-020-00707-2. PMID: 32065354

43. Tramontano D, Bini S, Maiorca C, Di Costanzo A, Carosi M, Castellese J, et al. Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions. Drugs. 2025; 85(6):755-775. doi: 10.1007/s40265-025-02158-0. PMID: 40106181

44. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al.; CLEAR Harmony Trial. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019; 380(11):1022-1032. doi: 10.1056/NEJMoa1803917. PMID: 30865796

45. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al.; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023; 388(15):1353-1364. doi: 10.1056/NEJMoa2215024. PMID: 36876740

46. Barale C, Melchionda E, Morotti A, Russo I. PCSK9 Biology and Its Role in Atherothrombosis. Int J Mol Sci. 2021; 22(11):5880. doi: 10.3390/ijms22115880. PMID: 34070931

47. Grzesk G, Dorota B, Wołowiec Ł, Wołowiec A, Osiak J, Kozakiewicz M, et al. Safety of PCSK9 inhibitors. Biomed Pharmacother. 2022; 156:113957. doi: 10.1016/j.biopha.2022.113957. PMID: 36411665

48. Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, et al. Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Rev. 2021; 73(3):924-967. doi: 10.1124/pharmrev.120.000096. PMID: 34088867

49. Mayer G, Dobrev D, Kaski JC, Semb AG, Huber K, Zirlik A, et al. Management of dyslipidaemia in patients with comorbidities: facing the challenge. Eur Heart J Cardiovasc Pharmacother. 2024; 10(7):608-613. doi: 10.1093/ehjcvp/pvae058. PMID: 39153964

50. Ikegami Y, Inoue I, Inoue K, Shinoda Y, Iida S, Goto S, et al. The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. NPJ Aging Mech Dis. 2018; 4:7. doi: 10.1038/s41514-018-0026-2. Erratum in: NPJ Aging. 2025; 11(1):19. doi: 10.1038/s41514-025-00208-1. PMID: 29951223

51. Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018; 93(6):1397-1408. doi: 10.1016/j.kint.2017.12.011. Epub 2018 Mar 8. PMID: 29526502

52. Alotaibi T, Nagib AM, Denewar A, Aboateya H, Halim MA, Mahmoud T, et al. Inhibition of Proprotein Convertase Subtilisin/Kexin-9 After Kidney Transplant: Single-Center Experience Among Patients With High Cardiovascular Risk. Exp Clin Transplant. 2024; 22(Suppl 1):315-322. doi: 10.6002/ect.MESOT2023.P111. PMID: 38385418

53. Воевода М.И., Гуревич В.С., Ежов М.В., Сергиенко И.В. Инклисиран — новая эра в гиполипидемической терапии. Кардиология. 2022;62(6):57-62. doi: 10.18087/cardio.2022.6.n2115.

54. Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmesser U, et al. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin Proc. 2020; 95(1):77-89. doi: 10.1016/j.mayocp.2019.08.021. PMID: 31630870

55. Ueberdiek L, Jehn U, Pavenstädt H, Gebauer K, Reuter S. Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient. Transpl Int. 2023 Jan 26;36:11104. doi: 10.3389/ti.2023.11104. Erratum in: Transpl Int. 2023; 36:11313. doi: 10.3389/ti.2023.11313. PMID: 36776901